2024/01/30
Editorial Column
To enhance the overall operational efficiency of the company, the Board of Directors of Medigen Biotech Corp has resolved to form a strategic alliance with Taiwan Exosome Company.
Major Information Announcement on the Public Information Observatory
(3176)Medigen Biotech Corp-Announcement of Important Resolutions of the Company's Board of Directors
1.Date of Occurrence:2024/01/30
2.Company Name: Medigen Biotech Corp.
3.Relationship with the Company(Please enter the parent company or subsidiary):parent company
4.Shareholding Ratio : Not Applicable
5.Reason for Occurrence :
To enhance the overall operational efficiency of the company, the Board of Directors has resolved to form a strategic alliance with Taiwan Exosome (Co.) Ltd. (referred to as Exosome Company). The cooperation details are as follows:
(1) Our company will sell related hardware and software assets (excluding real estate) of the Xizhi Cell Laboratory to Exosome Company at a disposal price of NT$220 million.
(2) A 100% owned investment company will invest in 50 million shares of Exosome Company at NT$2.50 per share, totaling NT$125 million, to participate in the cash capital increase. After this investment, our company will hold a 29.76% stake.
In the future, GigaGen Biotech will focus on new drug development in the field of cell therapy, with core business activities centered on conducting clinical trials to verify efficacy. Cell production will be outsourced to qualified cell preparation factories. Additionally, the company has high expectations for the research and development capabilities and long-term prospects of Exosome Company. Beyond equity investment, both parties will engage in business cooperation. Through this strategic alliance, it is expected to bring positive benefits to the company's financial performance and business.
6.Countermeasures:None
7.Other Matters to Be Noted(If the subject of the occurrence or resolution is a publicly listed company or above, this major information also complies with Article 7, Paragraph 9 of the Regulations for the Enforcement of the Securities and Exchange Act, which stipulates matters that have a significant impact on shareholder rights or securities prices.):None
(3176)Medigen Biotech Corp-Announcement of Important Resolutions of the Company's Board of Directors
1.Date of Occurrence:2024/01/30
2.Company Name: Medigen Biotech Corp.
3.Relationship with the Company(Please enter the parent company or subsidiary):parent company
4.Shareholding Ratio : Not Applicable
5.Reason for Occurrence :
To enhance the overall operational efficiency of the company, the Board of Directors has resolved to form a strategic alliance with Taiwan Exosome (Co.) Ltd. (referred to as Exosome Company). The cooperation details are as follows:
(1) Our company will sell related hardware and software assets (excluding real estate) of the Xizhi Cell Laboratory to Exosome Company at a disposal price of NT$220 million.
(2) A 100% owned investment company will invest in 50 million shares of Exosome Company at NT$2.50 per share, totaling NT$125 million, to participate in the cash capital increase. After this investment, our company will hold a 29.76% stake.
In the future, GigaGen Biotech will focus on new drug development in the field of cell therapy, with core business activities centered on conducting clinical trials to verify efficacy. Cell production will be outsourced to qualified cell preparation factories. Additionally, the company has high expectations for the research and development capabilities and long-term prospects of Exosome Company. Beyond equity investment, both parties will engage in business cooperation. Through this strategic alliance, it is expected to bring positive benefits to the company's financial performance and business.
6.Countermeasures:None
7.Other Matters to Be Noted(If the subject of the occurrence or resolution is a publicly listed company or above, this major information also complies with Article 7, Paragraph 9 of the Regulations for the Enforcement of the Securities and Exchange Act, which stipulates matters that have a significant impact on shareholder rights or securities prices.):None